Aspirin and/or Folic Acid in Preventing Recurrent Colorectal Polyps

NCT ID: NCT00033319

Last Updated: 2013-09-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

1997-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of aspirin and/or folic acid may be effective in preventing recurrent polyps in patients who have had polyps removed previously.

PURPOSE: Randomized clinical trial to determine the effectiveness of aspirin and/or folic acid in preventing the recurrence of colorectal polyps.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

* Determine whether aspirin and/or folic acid prevents recurrence of colorectal adenomas in patients who have had colorectal adenomas removed.

OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are randomized to 1 of 4 treatment arms.

* Arm I: Patients receive oral aspirin and oral folic acid daily.
* Arm II: Patients receive oral aspirin and oral placebo daily.
* Arm III: Patients receive oral placebo and oral folic acid daily.
* Arm IV: Patients receive 2 oral placebos daily. In all arms, treatment continues for 3 years in the absence of unacceptable toxicity.

After completion of the 3-year intervention, all patients undergo a surveillance colonoscopy.

Peer Reviewed and Funded or Endorsed by Cancer Research UK

PROJECTED ACCRUAL: A total of 1,300 patients will be accrued for this study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Cancer

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

colon cancer rectal cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

PREVENTION

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

folic acid

Intervention Type DIETARY_SUPPLEMENT

acetylsalicylic acid

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

DISEASE CHARACTERISTICS:

* Histologically confirmed colorectal adenoma removed within the past 6 months

* Greater than 0.5 cm after fixation or greater than 0.7 cm at time of removal

* OR
* Any size with a history of prior colorectal adenoma removal(s)
* Removed via colonoscopy, flexi-sigmoidoscopy (provided barium enema has been performed), or transanal endoscopic microsurgery
* Removal must be considered complete with follow-up to be done within 6 months
* No prior resection of large bowel (e.g., hemi-colectomy or greater, anterior resection, or subtotal colectomy)

PATIENT CHARACTERISTICS:

Age:

* 75 and under

Performance status:

* Not specified

Life expectancy:

* Not specified

Hematopoietic:

* No active bleeding disorders

Hepatic:

* Not specified

Renal:

* Not specified

Cardiovascular:

* No unstable heart conditions

Pulmonary:

* No unstable asthma

Other:

* Not pregnant and no potential to become pregnant within the next 3 years
* No unstable diabetes
* No active upper gastrointestinal ulceration
* No known aspirin intolerance or sensitivity
* No other serious medical conditions that would preclude study participation

PRIOR CONCURRENT THERAPY:

Biologic therapy:

* Not specified

Chemotherapy:

* Not specified

Endocrine therapy:

* Not specified

Radiotherapy:

* Not specified

Surgery:

* See Disease Characteristics

Other:

* No other concurrent folic acid
* No concurrent anticoagulants
* No other prior or concurrent non-steroidal anti-inflammatory drugs, prescribed or self-medicated (more than 3 tablets per week)
Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Queen's Medical Center

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Richard Logan, MD

Role: STUDY_CHAIR

Queen's Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Antrim Hospital

Antrim, England, United Kingdom

Site Status

City Hospital - Birmingham

Birmingham, England, United Kingdom

Site Status

Birmingham Heartlands and Solihull NHS Trust (Teaching)

Birmingham, England, United Kingdom

Site Status

Southmead Hospital

Bristol, England, United Kingdom

Site Status

Frenchay Hospital

Bristol, England, United Kingdom

Site Status

Bristol Royal Infirmary

Bristol, England, United Kingdom

Site Status

Derby City General Hospital

Derby, England, United Kingdom

Site Status

Wordsley Hospital

Dudley, England, United Kingdom

Site Status

Glenfield Hospital

Leicester, England, United Kingdom

Site Status

Royal Liverpool and Broadgreen Hospitals

Liverpool, England, United Kingdom

Site Status

Manchester Royal Infirmary

Manchester, England, United Kingdom

Site Status

Wythenshawe Hospital

Manchester, England, United Kingdom

Site Status

Trafford General Hospital

Manchester, England, United Kingdom

Site Status

Southport and Formby District General Hospital

Merseyside, England, United Kingdom

Site Status

Merthyr Tydfil Hospital

Merthyr, England, United Kingdom

Site Status

Nottingham City Hospital NHS Trust

Nottingham, England, United Kingdom

Site Status

Queen's Medical Centre

Nottingham, England, United Kingdom

Site Status

Whiston Hospital

Prescot Merseyside, England, United Kingdom

Site Status

Salford Royal Hospitals NHS Trust

Salford, England, United Kingdom

Site Status

Sheffield Teaching Hospitals

Sheffield, England, United Kingdom

Site Status

Northern General Hospital

Sheffield, England, United Kingdom

Site Status

Solihull Hospital

Solihull, England, United Kingdom

Site Status

Royal Victoria Hospital

Belfast, Northern Ireland, United Kingdom

Site Status

Whiteabbey Hospital

Newtownabbey, Northern Ireland, United Kingdom

Site Status

Princess of Wales Hospital

Bridgend, Wales, United Kingdom

Site Status

University of Wales College of Medicine

Cardiff, Wales, United Kingdom

Site Status

Selly Oak Hospital

Birmingham, , United Kingdom

Site Status

East Glamorgan Hospital

Lhantrisant, , United Kingdom

Site Status

North Manchester Healthcare NHS Trust

Manchester, , United Kingdom

Site Status

Royal Gwent Hospital

Newport Gwent, , United Kingdom

Site Status

King's Mills Hospital

Nottinghamshire, , United Kingdom

Site Status

Rotherham District General Hospital-NHS Trust

Rotherham, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

QMC-UKCAP

Identifier Type: -

Identifier Source: secondary_id

EU-20045

Identifier Type: -

Identifier Source: secondary_id

CDR0000069273

Identifier Type: -

Identifier Source: org_study_id